calcipotriene

(redirected from Sorilux)
Also found in: Dictionary.
Related to Sorilux: Calcipotriene, Dovonex

calcipotriene

 [kal″sĭ-po-tri´ēn]
a synthetic derivative of cholecalciferol (vitamin D3), applied to the skin to treat psoriasis.

calcipotriene

A topical vitamin-D analogue with minimum effects on vitamin-D metabolism, which is FDA-approved for treating mild-to-moderate psoriasis; it is similar in efficacy to topical corticosteroids.

Adverse effects
Rarely, hypercalcaemia.
References in periodicals archive ?
In addition there are a number of other ongoing clinical trials assessing the efficacy and tolerability of new indications or label extensions for products like SUBA-itraconazole, FABIOR, LEXETTE and SORILUX, some of which are investigator initiated studies.
The US Food and Drug Administration (FDA) has approved Australia-based Mayne Pharma Group Limited's (ASX: MYX) SORILUX (calcipotriene) Foam, 0.005% to treat adolescents, it was reported yesterday.
SORILUX Foam contains calcipotriene, a synthetic vitamin D analogue that has a similar receptor binding affinity as natural vitamin D.
Pharmaceutical company Mayne Pharma Group Limited (ASX:MYX) reported on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) for SORILUX (calcipotriene) Foam, 0.005%, for treating plaque psoriasis of the scalp and body in patients aged 12 years and older.
According to the company, SORILUX Foam contains calcipotriene, a synthetic vitamin D analog that has a similar receptor binding affinity as natural vitamin D.
The FDA originally approved SORILUX in 2010 based on evidence from the company's two, eight-week placebo controlled clinical trials in patients with mild to moderate plaque psoriasis of the body plus one, eight-week placebo controlled clinical trial in patients with moderate plaque psoriasis of the scalp.
Both Fabior and Sorilux will be marketed through Mayne Pharma's Specialty Brands Division and existing sales team.
During the intervening period GSK will continue to distribute Fabior and Sorilux under a transition services arrangement.
Sorilux (calcipotriene) Foam, 0.005% is a patent-protected topical product indicated for mild to moderate plaque psoriasis affecting up to 6 million Americans each year.
Both Fabior and Sorilux will be marketed through Mayne Pharmas Specialty Brands Division and existing sales team.